The Study
Targeting Cysteine 42 in PKGIa limits diastolic dysfunction in HFpEF
This study tested a chemical on mice and lab-grown heart tissue, and saw that it made their hearts work better. But it didn't test it on real people with heart problems, so we don't know if it would help humans at all.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
A natural compound called urolithin A, found in pomegranates, helps the heart relax better by turning on a specific protein (PKGIα) at a tiny spot called C42.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 555 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — if this works in humans, it could help millions with HFpEF who currently have no good treatments.
- 2In mice with heart failure, urolithin A improved heart relaxation; in mice with a mutated C42 spot, it did nothing.
- 3In human heart tissue, it made the heart beat more efficiently.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Related Content
Claims (6)
Urolithin A causes a specific chemical change at cysteine 42 in the PKGIα protein, leading to its activation in laboratory protein systems, rat blood vessel cells, and rat heart cells.
Urolithin A increases the speed of relaxation and contraction in human heart tissue grown in the lab by activating the protein PKGIα.
Urolithin A enhances heart relaxation and prevents harmful structural changes in mice with heart failure and preserved ejection fraction by triggering a specific chemical modification in the PKGIα protein at cysteine 42, and this effect is lost when that modification site is genetically altered.
In mice with heart failure with preserved ejection fraction, urolithin A protects the heart only if the protein PKGIα has cysteine at position 42; replacing this amino acid eliminates the protective effect.
Urolithin A triggers a specific biochemical change in heart muscle cells from newborn rats, involving the phosphorylation of phospholamban through the PKGIα pathway.
Urolithin A increases the removal of damaged mitochondria and improves mitochondrial function in heart tissue, which reduces heart tissue damage.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.